DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
A prospective multicenter study of 912 patients published in Dermatology and Therapy showed Castle Biosciences' DecisionDx-Melanoma's i31-SLNB test outperformed the MIA nomogram in identifying patients who may safely avoid sentinel lymph node biopsy. Patients classified as low risk by i31-SLNB had a 2.6% observed SLN positivity rate, below the 5% NCCN threshold, compared to 5.8% for the MIA nomogram. The test demonstrated greater discriminative performance than the clinicopathologic-only MIA nomogram (AUC=0.74 vs.
Key figures
- Auc i31 slnb
- 0.74
- Patient count
- 912
- Nccn threshold
- 5%
- Auc mia nomogram
- 0.61
- I31 slnb low risk positivity rate
- 2.6%
- Mia nomogram low risk positivity rate
- 5.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.